Related Experiment Video
Updated: May 29, 2026

Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
Current management and recommendations for access to antiviral therapy of herpes labialis
Anthony Cunningham1, Paul Griffiths, Peter Leone
1Westmead Millennium Institute and University of Sydney, Westmead, NSW 2145, Australia.
Abstract:
Herpes labialis is a common skin infective condition, worldwide, which is primarily caused by HSV-1. Recurrent episodes of herpes labialis, also known as cold sores, can be frequent, painful, long-lasting and disfiguring for infected patients. At present, there are two types of antivirals for the treatment of herpes labialis, topical and oral, which are available over the counter or as prescription-only. The aim of antiviral therapy is to block viral replication to enable shortening the duration of symptoms and to accelerate healing of the lesions associated with herpes labialis. This review examines the evidence for the effectiveness of current topical and oral antivirals in the management of recurrent episodes of herpes labialis. In most countries, oral antivirals for herpes labialis are available as prescription-only. However, in early 2010, the oral antiviral famciclovir was reclassified from prescription-only medicine to pharmacist-controlled status in New Zealand. The benefits and risks associated with moving an antiviral therapy for herpes labialis from prescription-only to pharmacist-controlled status are reviewed here, and the implications for patients, general physicians and pharmacists are considered.
Related Concept Videos
Herpes
Genital Herpes
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Tonsillitis II: Management
Inhibitors of Viral Protein Synthesis

